We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Ecarin Chromogenic Assay Provides Precise DTI Results

By LabMedica International staff writers
Posted on 29 Nov 2010
The ecarin chromogenic assay (ECA) is a highly specific tool for determining the exact direct thrombin inhibitor (DTI) concentration in plasma without interference from abnormal prothrombin or fibrinogen levels.

ECA results are independent of coagulation factors and plasmatic inhibitors within the sample; and as it is not influenced by lupus anticoagulants, the assay allows for specific determinations.

The assay is insensitive to heparin, LMWH, danaparoid, fondaparinux, and direct factor Xa antagonists. More...
This facilitates bridging and transition to other anticoagulants, and dosage adaptation in high-risk patients. Additionally, the ECA dose response results are linear and do not plateau at elevated concentrations.

A Diagnostica Stago, Inc. (Stago; Parsippany, NJ, USA) product, the ECA kit can be adapted to the company's automated instruments. The wide measuring range includes two reagent formats dedicated to each DTI type (ECA-H for recombinant hirudins, ECA-T for synthetic DTIs). Recombinant hirudins include desirudin (Revasc, Iprivask) and lepirudin (Refludan). DTIs include argatroban (Argatroban), bivalirudin (Angiomax), and dabigatran etexilate (Pradaxa). Specific standards and controls are also available.

Related Links:

Diagnostica Stago





Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: HBV RNA in blood is as a stronger predictor of liver cancer risk in patients treated for chronic hepatitis B (Photo courtesy of Adobe Stock)

New Biomarkers Indicate Higher Liver Cancer Risk in Chronic Hepatitis B Patients

Chronic hepatitis B affects around 296 million people worldwide and is a major cause of liver cirrhosis and liver cancer. While modern antiviral treatments can suppress the virus and significantly improve... Read more

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.